

Registration www.meeting-com.ch

Final Program



48th Annual Meeting Swiss Society of Nephrology

Interlaken, Kursaal
December 8-9, 2016

Schweizerische Gesellschaft für Nephrologie
Société Suisse de Néphrologie
Società Svizzera di Nefrologia

NEPHRO
SWISS SOCIETY OF NEPHROLOGY

www.swissnephrology.ch

Symposia

December 7, 2016

Basics in Nephrology

December 9, 2016

Pflege in der Nephrologie / Soins en Néphrologie /
Cure in Nefrologia

6008 CAREsystem

We take care of the complexity –
so you can take care of what matters.



The new 6008 CAREsystem offers a simplified design to deliver advanced dialysis and enable better care for patients.

6008 CAREsystem
More care. Less complexity.

Visit us at
SGN-SSN 2016



Fresenius Medical Care (Schweiz) AG · Aawasserstrasse 2 · 6370 Oberdorf NW
Telefon +41 (0)41 619 50 50 · Fax +41 (0)41 619 50 80 · info.ch@fmc-ag.com · www.fresenius.ch

Invitation 2016

Dear Colleagues,

With great pleasure we invite you to the 48th annual meeting of the Swiss Society of Nephrology in Interlaken.

The innovation of the 2016 meeting will be a more complete and effective integration of nephrology nurses into the congress. Strengthening the links between nephrologists and nurses, with the aim of acquiring a common knowledge and of developing a combined approach to many shared issues, is becoming increasingly important and critical.

After a successful revival last year, the poster walk will be taken one step further and the question time will be increased in each of the "big four" in nephrology: basic science, clinical nephrology, dialysis and transplantation.

The CME will be focused on clinical nephrology and dialysis with lectures centered on three critical issues: nephrolithiasis, hypertension, and hyperkalemia, hypotension and disequilibrium in hemodialysis.

The state of the art lectures will be dedicated to four topics of current interest for our community; acute kidney injury, cardiorenal syndrome, anticoagulation on dialysis and bioengineering in nephrology.

Our industry partners have taken great care to support the society meeting and sponsor symposia with scientific value which we encourage you to view as a full part of the scientific program.

Last but not least, on Friday afternoon, the farewell words of the president of the society will be preceded by a session shared with the nurses and dedicated to three hot topics: dialysis withdrawal, medication adherence and potential toxicity of herbal remedies.

So let's meet again in Interlaken, share the amazing research, knowledge and projects which come from our very active nephrology community; let's also meet each other again and enjoy a familial place.

Congress presidents SGN-SSN 2016

Dr Isabelle Binet
Kantonsspital St. Gallen

Prof. Luca Gabutti
Ospedale Regionale di Bellinzona e Valli

Table of contents

Invitation 2016	3
Organization	5
General information	6
Program at a glance	9
Scientific Program – Basics in Nephrology	12
Scientific Program	13
Congress Dinner	22
Scientific Program – Pflege in der Nephrologie	23
Poster presentations	33
Speakers / Moderators	47
Exhibitors	49
Sponsored symposia in alphabetical order	50
Sponsors	52
SGN-SSN congress 2017	54

Organization

Congress Presidents	Isabelle Binet, Kantonsspital St. Gallen Luca Gabutti, Ospedale Regionale di Bellinzona e Valli, Bellinzona
Scientific Committee	Stefan Farese, Solothurn Olivier Giannini, Mendrisio Déla Golshayan, Lausanne Uyen Huynh-Do, Bern Andreas Kistler, Frauenfeld Nilufar Mohebbi, Zürich Patrick Saudan, Genève Stefan Schaub, Basel Daniel Teta, Sion Dimitrios Tsinalis, St. Gallen
Board of the SGN-SSN	President 2016-2017 Pierre-Yves Martin, HUG, Genève President-elect Uyen Huynh-Do, Inselspital, Bern Past President Jürg Steiger, Universitätsspital, Basel Secretary Olivier Bonny, CHUV, Lausanne Treasurer Patrick Wilson, Hôpital du Jura, Delémont Pediatric Nephrologist Thomas J. Neuhaus, Kinderspital LUKS, Luzern Dialysis Commission Dominik E. Uehlinger, Inselspital, Bern Board Members Andreas Bock, Kantonsspital, Aarau Olivier Devuyst, Institute of Physiology, Zürich Daniel Fuster, Inselspital, Bern Luca Gabutti, Ospedale Regionale, Bellinzona Ann-Kathrin Schwarzkopf, Hirslanden Bern AG, Bern

General information

Congress venue	Congress Centre Kursaal Interlaken Strandbadstrasse 44, 3800 Interlaken www.congress-interlaken.ch
Registration & congress secretariat	Meeting.com Congress Organisation Rue des Pâquis 1, CP 100, CH-1033 Cheseaux-sur-Lausanne Online registration on: www.meeting-com.ch T +41 21 312 9261 – F +41 21 312 9263 – E info@meeting-com.ch Onsite registration also possible (onsite fee)

Registration fee for congress	Early fee (before Nov. 1, 2016)	Late fee (Nov. 2-29, 2016)	Onsite fee (From Nov. 30, 2016)
Member SGN-SSN	CHF 230.00	CHF 270.00	CHF 300.00
Non-member	CHF 280.00	CHF 320.00	CHF 360.00
Trainees / Residents / Students*	CHF 150.00	CHF 180.00	CHF 210.00
Pflege / Nurses / Infirmiers-ères	CHF 100.00	CHF 120.00	CHF 150.00
<i>NCCR-Member</i>	<i>CHF 150.00</i>	<i>CHF 180.00</i>	<i>CHF 210.00</i>

The registration fee includes: access to the scientific sessions, congress documents and lunches. The Congress Dinner is not included and has to be booked separately when registering (CHF 90.00). Places are limited and a reservation is required.

*In order to benefit from the reduced fee, students or residents are required to send a document confirming their status to the SGN-SSN 2016 Congress Management by fax or scanned within 7 days from the date of registration.

Registration fee for Symposium 7.12.16	Early fee (before Nov. 1, 2016)	Late fee (Nov. 2-29, 2016)	Onsite fee (From Nov. 30, 2016)
Basics in Nephrology	CHF 100.00	CHF 120.00	CHF 150.00

Separate registration is required using the online-registration on www.meeting-com.ch.

Payment	Upon registration you will receive a confirmation by email together with the banking details for the payment. Payment by credit card upon registration is possible.
----------------	---

General information

Congress management	Meeting.com Congress Organisation Mrs Nicole Giacomini Rue des Pâquis 1, CP 100, 1033 Cheseaux-sur-Lausanne T +41 21 312 9161, F +41 21 312 9263 nicole.giacomini@meeting-com.ch , www.meeting-com.ch
----------------------------	--

Certificate of participation	The certificate of participation will be available online and downloadable after the congress. A link will be sent to all participants accordingly.
-------------------------------------	---

Cancellation	Written notification is required for all cancellations and changes. In case of cancellation 30 days prior the event, the refund of the amount paid will be done net of CHF 60.00 for administrative costs. Thereafter no refund possible. Any registration made within the "early bird" time must be paid during this period. If not the case, the invoice is automatically updated at the current price. Administrative costs will be charged to no shows. Legal jurisdiction is Lausanne.
---------------------	---

Industrial exhibition	An industrial exhibition will take place at the Congress Venue. It will be open throughout the congress. Coffee (breaks) will be offered by exhibitors.
------------------------------	---

Hotel booking	Hotel reservation possible with Interlaken Tourismus on www.interlaken.ch .
----------------------	--

Abstracts	The abstracts must be submitted until September 11, 2016, only via Internet on www.swissnephrology.ch . The deadline will not be extended.
------------------	--

Confirmation	Scientific contributions (oral presentations and posters) will be reviewed and confirmed to authors by e-mail in week 40.
---------------------	---

Oral Presentations	The Scientific Committee will select a number of abstracts which will be presented as oral presentations. Speaking time: 8 min and 2 min discussion.
---------------------------	--

General information

Posters	The abstracts accepted as poster will be presented in the poster exhibition. Dimensions of posters: height 120 cm x width 90 cm (portrait).
Posterwalk	There will be an organized Posterwalk on Thursday, December 8, from 17 h 30 to 18 h 30 where the highest rated posters in each category will receive the Poster Prize Award : – Clinical Nephrology / Hypertension / Mineral / Electrolytes – Basic Science / Genetics / Experimental Nephrology – Hemodialysis (HD) / Peritoneal Dialysis (PD) – Transplantation we thank each author to be present near his / her poster during the posterwalk
Poster Prize Awards	will take place during the Congress Dinner on December 8, 2016.
Registration	Authors presenting an accepted paper or poster must register to attend the meeting and pay the appropriate registration fee.
Credits	Credits points will be given by the following societies: SGN-SSN Congress, December 8-9, 2016 SGN-SSN 16 credits SGAIM-SSMIG 11.5 credits Basics in Nephrology, December 7, 2016 SGN-SSN 4 credits SGAIM-SSMIG 4 credits
Language	Lectures in English, discussion in German, French or English. The Symposium "Pflege in der Nephrologie" will be held in German, French and Italian

Program at a glance

Wednesday, December 7, 2016

	Special CME Symposium Basics in Nephrology Course
Time	Room A
From 12.00	Registration
13.00-15.00	Plenary sessions
15.00-15.30	Coffee Break
15.30-17.30	Plenary sessions
17.30	End of Basics in Nephrology Course

Program at a glance

Thursday, December 8, 2016

Time	Room A	Room B
From 8.00	Registration	
09.45	Welcome Address	
09.45-10.45	State of the Art Lectures	
10.45-11.15	Coffee break – Visit of the exhibition – Poster viewing	
11.15-12.15	Oral Parallel Presentations Basic Science / Genetics / Experimental Nephrology	Oral Parallel Presentations Transplantation
12.15-12.30	Short break	
12.30-13.15	Satellite Lunch Symposium Sponsored by BOEHRINGER	
13.15-14.00	Standing lunch at the exhibition – Poster viewing	
14.00-15.00	Symposium WGIKD	Symposium NCCR Kidney.CH
15.00-15.30	Coffee break – Visit of the exhibition	
15.30-16.15	Satellite Symposium Sponsored by AMGEN	
16.15-16.30	Short break	
16.30-17.30	State of The Art Lectures	
17.30-18.30	Posterwalk in the Exhibition	
18.45	WELCOME DRINK & CONGRESS DINNER with Poster Prize Awards	

Program at a glance

Friday December 9, 2016

Time	Room A	Room B	Room Brünig
From 07.00	Registration		
07.45-09.15	General assembly SGN-SSN		
09.15-09.45	The Swiss Dialysis Registry		
09.45-10.00	SGN-SSN Publication Award 2016		
10.00-11.00	State of the Art Lectures		10.00-10.50 Pflege in der Nephrologie
11.00-11.30	Coffee break – Visit of the exhibition & posters		
11.30-12.15	Satellite Symposium Sponsored by VIFOR	Satellite Symposium Sponsored by BAXTER	11.30-12.15 Pflege in der Nephrologie
12.15-13.00	News from IICT		12.15-13.00 Pflege in der Nephrologie
13.00-14.00	Coffee break – Visit of the exhibition & posters		
14.00-15.00	Oral Parallel Presentations Clinical Nephrology / Hypertension / Mineral / Electrolytes	Oral Parallel Presentations Hemodialysis (HD) / Peritoneal Dialysis (PD)	
15.00-15.15	Coffee break – Visit of the exhibition & posters		
15.15-16.30	Hot Topics		
16.30	Farewell		

Wednesday, December 7

Room A

Satellite CME Symposium: Basics in Nephrology

Frequent questions in clinical nephrology and analysis

From 12.00 Registration

Chairs: Luca Gabutti, Bellinzona; Patrick Wilson, Delémont

13.00-13.40 Nephrolithiasis from pathophysiology to diagnosis and treatment
Olivier Bonny, Lausanne

13.40-14.00 Presentation of a case and discussion
Olivier Bonny, Lausanne; Luca Gabutti, Bellinzona

14.00-14.40 Hypertension with or without renal insufficiency, what do we need to know?
Michel Burnier, Lausanne

14.40-15.00 Presentation of a case and discussion
Michel Burnier, Lausanne; Patrick Wilson, Delémont

15.00-15.30 Coffee break (in Room A)

Chairs: Isabelle Binet, St. Gallen; Ann-Kathrin Schwarzkopf, Bern

15.30-16.10 How to deal with hyperkalemia on dialysis
Andreas Fischer, Luzern

16.10-16.50 How to deal with hypotension on dialysis
Andreas Kistler, Frauenfeld

16.50-17.30 How to deal with disequilibrium on dialysis
Dimitrios Tsinalis, St. Gallen

17.30 End of Basics in Nephrology Course

Thursday, December 8

Swiss Society of Nephrology Congress

From 08.00 Registration

09.45 Opening of the 48th Annual Meeting of the Swiss Society of Nephrology

Room A

09.45-09.50 Welcome Address
Isabelle Binet, St. Gallen; Luca Gabutti, Bellinzona

09.50-10.45 State of The Art Lectures ACUTE KIDNEY INJURY
Chairs: Rudolf Wüthrich, Zürich; Bruno Vogt, Bern

Room A

09.50-10.15 **Epidemiology and Clinical Aspects**
Karl Lhotta, Feldkirch (AT)

10.15-10.40 **New aspects in basic research**
Nicolas Pallet, Paris (F)

10.45-11.15 Coffee break – Visit of the exhibition – Poster viewing Exhibition space

11.15-12.15 Oral Parallel Presentations Basic Science / Genetics / Experimental Nephrology
11.15-12.15 *Chairs: Nilufar Mohebbi, Zürich; Daniel Fuster, Bern*
6 oral presentations

Room A

11.15-12.15 **Transplantation**
Chairs: Stefan Schaub, Basel; Déla Golshayan, Lausanne
6 oral presentations

Room B

12.15-12.30 Short break

Oral communications

Oral Parallel Presentations

11.15-12.15 Basic Science / Genetics / Experimental Nephrology **Room A**

Chairs: Nilufar Mohebbi, Zürich; Daniel Fuster, Bern

- OC 01** **Cross-talk between oxygen sensing and sodium handling in the collecting duct "NCCR project"**
Eva Dizin¹, Khalil Udwan¹, Isabelle Roth¹, Charline Maire¹, Edith Hummler², Ian Frew³, Eric Feraille¹
¹UNIGE, Geneva; ²UNIL, Lausanne; ³Institute of Physiology, University of Zurich, Zurich
- OC 02** **Phenotype and disease severity reflected by serum lysoGB3 levels in patients with Fabry disease**
Albina Nowak¹, Thomas Mechtler², Pierre-Alexandre Krayenbuehl³, Uyen Huynh-Do⁴, David Kasper²
¹University Hospital Zurich, Zurich; ²ARCHIMED Life Science, Vienna (AT); ³Linth Hospital, Uznach; ⁴Department of Nephrology, Hypertension and Clinical Pharmacology, University Hospital Bern, Bern
- OC 03** **Hypophosphatasia in mice deleted for the redox protein MEMO. NCCR Kidney.CH project**
Matthias Moor¹, Suresh Ramakrishnan¹, Finola Legrand¹, Silvia Dolder², Mark Siegrist², Barbara Haenzi³, Nancy Hynes⁴, Willy Hofstetter², Olivier Bonny⁵
¹Department of Pharmacology and Toxicology, University of Lausanne, Lausanne; ²Department für Klinische Forschung, University of Bern, Bern; ³Department of clinical neuroscience, University of Cambridge (UK); ⁴Friedrich Mischer Institute, Basel; ⁵University Hospital Lausanne, Lausanne

Oral communications

- OC 04** **A single nucleotide polymorphism (SNP) in FSHR determines degree of liver involvement in female ADPKD patients (NCCR project)**
Daniel Sidler¹, Stefan Rudloff¹, Ajay Panakal¹, Daniel Fuster^{1,2}, Emanuel Christ³, Uyen Huynh-Do¹
¹Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, University Hospital, Bern; ²Institute of Biochemistry and Molecular Medicine, University of Bern, Bern; ³Clinic for Diabetology, Endocrinology, Nutritional Medicine & Metabolism, Inselspital, University Hospital, Bern
- OC 5** **The effect of dietary phosphate intake on blood pressure regulation and renal sodium chloride excretion in healthy male volunteers (NCCR Project)**
Jennifer Scotti Gerber¹, Arezoo Daryadel², Harald Seeger¹, Isabella Sudano¹, Carsten Wagner², Nilufar Mohebbi³
¹University Hospital of Zurich, Zurich; ²Institute of Physiology, University of Zurich, Zurich; ³Division of Nephrology, University Hospital, Zurich
- OC 6** **Renal erythropoietin producing cells in vivo_NCCR Project**
Karen Nolan¹, Willy Kuo², Faik Imeri¹, Svende Pfundstein¹, Irene Abreu-Rodriguez¹, Patrick Spielmann¹, Edith Hummler³, Vartan Kurtcuoglu², Carsten Scholz², David Hoogewijs⁴, Roland Wenger⁵
¹Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich; ²Institute of Physiology, University of Zurich, Zurich; ³UNIL, Lausanne; ⁴Medizinische Fakultät, Universitätsklinikum Essen, Essen (DE); ⁵Institute of Physiology and Zurich Center for Integrative Human Physiology, National Centre of Competence in Research "Kidney.CH", University of Zurich, Zurich

Oral communications

Oral Parallel Presentations

11.15-12.15

Transplantation

Room B

Chairs: Stefan Schaub, Basel; Déla Golshayan, Lausanne

OC 07 **Infections in de novo kidney transplant recipients treated with the RANKL inhibitor denosumab**

Marco Bonani¹, Diana Frey², Olivier De Rougemont³, Nicolas Müller⁴, Thomas Müller¹, Nicole Graf⁵, Rudolf Wüthrich¹

¹Division of Nephrology, University Hospital Zurich, Zurich; ²Division of Rheumatology, University Hospital Zurich, Zurich; ³Division of Visceral and Transplantation Surgery, University Hospital Zurich, Zurich; ⁴Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich; ⁵Graf Biostatistics, Winterthur

OC 08 **C1q blocking effects of week/non-complement-binding HLA antibodies**

Gideon Hönger¹, Patrizia Amico², Marlies Arnold³, Bernd Spriewald³, Stefan Schaub²

¹Transplantation Immunology, Department of Biomedicine, University Basel, Basel; ²Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel; ³Laboratory for Immunogenetics, University Erlangen (DE)

OC 09 **Early complications after living donor nephrectomy: a prospective analysis of the Swiss Organ-Living Donor Health Registry**

Felix Burkhalter¹, Uyen Huynh-Do², Karine Hadaya³, Maurice Matter⁴, Thomas Müller⁵, Isabelle Binet⁶, Christa Nolte⁷, Jürg Steiger¹

¹Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel; ²Department of Nephrology, Hypertension and Clinical Pharmacology, University Hospital Bern, Bern; ³Department of Nephrology, University Hospital of Geneva, Geneva; ⁴Department of Visceral Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne; ⁵Division of Nephrology, University Hospital Zurich, Zurich; ⁶Nephrology and Transplantation medicine, Kantonsspital St Gallen, St-Gallen; ⁷Swiss Organ-Living Donor Health Registry, University Hospital of Basel, Basel

Oral communications

OC 10

Frequency and predictors of successful steroid withdrawal guided by surveillance biopsies

Caroline Wehmeier¹, Patricia Hirt-Minkowski¹, Patrizia Amico¹, Argyrios Georgalis¹, Helmut Hopfer², Jürg Steiger¹, Michael Dickenmann¹, Stefan Schaub¹

¹Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel; ²Institute for Pathology, University Hospital Basel, Basel

OC 11

Long-term outcome of kidney transplantation in Fabry disease

Sara Ersözlü¹, Uyen Huynh-Do², Pietro Cippa³, Thomas Müller³, Albina Nowak¹

¹Department of Internal Medicine, University Hospital Zurich and University of Zurich, Zurich; ²Department of Nephrology, Hypertension and Clinical Pharmacology, Department of Clinical Research, Inselspital, University of Bern, Bern; ³Department of Nephrology, University Hospital Zurich and University of Zurich, Zurich

OC 12

Significance of isolated v-lesions on long-term graft survival in kidney transplantation

Argyrios Georgalis¹, Caroline Wehmeier¹, Patricia Hirt-Minkowski¹, Gideon Hönger¹, Helmut Hopfer², Jürg Steiger¹, Stefan Schaub¹, Patrizia Amico¹

¹Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel; ²Institute for Pathology, University Hospital Basel, Basel

Boehringer Ingelheim Symposium, Room A

Thursday, 8th December 2016

Lunch: 12.30 - 13.15 h

48th Annual Meeting of the Swiss Society of Nephrology



Results & Conclusions from an Endocrinologist's and Nephrologist's Perspective

- Speaker:**
- PD Dr. med. Anne Zanchi-Delacrétaz
 - Prof. Dr. med. Michel Burnier
- Chairman:**
- Prof. Dr. med. Pierre-Yves Martin

We are looking forward to seeing you!

Thursday, December 8

12.30-13.15	Satellite Lunch Symposium Sponsored by BOEHRINGER	Boehringer Ingelheim	Room A
	EMPA-REG OUTCOME®: Results & Conclusions from an Endocrinologist's and Nephrologist's Perspective <i>Chair: Pierre-Yves Martin, Geneva</i> Anne Zanchi-Delacrétaz, Lausanne ; Michel Burnier, Lausanne		
13.15-14.00	Standing lunch at the exhibition – Poster viewing		Exhibition space
14.00-15.00	Parallel Symposia		Room A
14.00-15.00	Symposium WGKD		Room B
14.00-15.00	Symposium NCCR Kidney.CH <i>Chairs: François Verrey, Zürich; Sophie De Seigneux, Genève</i>		Room B
14.00-14.30	Renal contribution to erythrocyte homeostasis Vartan Kurtcuoglu, Zürich		
14.30-15.00	Live imaging of mitochondrial dysfunction in AKI Andrew Hall, Zürich		
15.00-15.30	Coffee break – Visit of the exhibition – Poster viewing		Exhibition space

AMGEN[®]

invites you to a Scientific Symposium

Individualizing treatment of CKD-MBD patients: Shaping the future

Thursday 8th of December 2016
from 3.30 pm – 4.15 pm

Chair:

Professor Pierre-Yves Martin
HUG Genève, Switzerland

Speaker:

Dr Pablo Antonio Ureña Torres
University of Paris Descartes, Paris, France

AMGEN[®]

AMGEN Switzerland AG, Dammstrasse 21, 6301 Zug, www.amgen.ch

CH-NP-CRP-0916-038332

Thursday, December 8

15.30-16.15	Satellite Symposium Sponsored by AMGEN	AMGEN [®]	Room A
	Individualizing treatment of CKD-MBD patients: shaping the future <i>Chair: Pierre-Yves Martin, Geneva Pablo Antonio Ureña Torres, Paris (F)</i>		
16.15-16.30	Short break		
16.30-17.30	State of The Art Lectures FROM EVERY DAY TO THE FUTURE <i>Chairs: Olivier Giannini, Mendrisio; Daniel Teta, Sion</i>		Room A
16.30-17.00	Anticoagulation on dialysis Simonetta Genovesi, Milan (IT)		
17.00-17.30	Bioengineered vessels and kidneys Suchitra Sumitran-Holgersson, Göteborg (SE)		
17.30-18.30	Poster walk		Poster Area
Topics Jury	– Clinical Nephrology / Hypertension / Mineral / Electrolytes Thomas Fehr, Chur; Andreas Bock, Aarau		
Topics Jury	– Basic science / Genetics / Experimental Nephrology Sophie de Seigneux, Genève; Daniel Fuster, Bern		
Topics Jury	– Hemodialysis (HD) / Peritoneal Dialysis (PD) Stephan Segerer, Zürich; Reto Venzin, Chur		
Topic Jury	– Transplantation Patrizia Amico, Basel; Thomas Müller, Zürich		
18.45	WELCOME DRINK & CONGRESS DINNER Poster Prize Awards		

Thursday, December 8

Room B / Ballsaal

CONGRESS DINNER

18.45 WELCOME DRINK & CONGRESS DINNER
Poster Prize Awards



The magnificent rooms of the Casino Kursaal Interlaken date from the 19th century and provide a perfect setting for the Congress Dinner of the Swiss Society of Nephrology.

You will enjoy this unique atmosphere, combined with first-class service and excellent cuisine.

We await your reservation with pleasure when registering online on www.meeting-com.ch. Pre-reservation is highly recommended. Additional tickets will be available at the registration desk on a first come first served basis.

Price: CHF 90.00/ticket

Congress Centre Kursaal Interlaken – Strandbadstrasse 44 – 3800 Interlaken

Friday, December 9

Swiss Society of Nephrology Congress

Special Satellite Symposium: Pflege in der Nephrologie / Soins en Néphrologie / Cure in Nefrologia

From 07.00	Registration	
07.45-09.15	GENERAL ASSEMBLY SGN-SSN	Room A
09.15-09.45	The Swiss Dialysis Registry Patrice Ambühl, Zürich <i>Chair: Pierre-Yves Martin, Genève</i>	Room A
09.45-10.00	SGN-SSN Publication Award 2016 <i>Chair: Pierre-Yves Martin, Genève</i> Presentation and short address Abhijeet Todkar, Freiburg im Breisgau (D) <i>Mechanisms of Renal Control of Potassium Homeostasis in Complete Aldosterone Deficiency</i>	Room A
10.00-11.00	State of the Art Lectures MANAGEMENT OF CARDIORENAL SYNDROME IN 2016 <i>Chairs: Uyen Huynh-Do, Bern; Carlo Schönholzer, Lugano</i>	Room A
10.00-10.30	The nephrologist approach Pierre-Yves Martin, Genève	
10.30-11.00	The cardiologist approach Andreas Flammer, Zürich	
10.00-10.50	Pflege in der Nephrologie / Soins en Néphrologie / Cure in Nefrologia <i>Vorsitz: Claudia Studer, Zürich; Ursula Dietrich, Bern; Irma König, Bellinzona</i> Dal curare al prendersi cura Du traitement de la maladie au soin global Von der Behandlung hin zur Pflege Marco Minniti, Mendrisio; Susanna Calcaterra, Lugano	Room Brünig
11.00-11.30	Coffee break – Visit of the exhibition & posters	Exhibition space



CURRENT AND EMERGING NEW OPTIONS TO REDUCE RISK FACTORS

Friday, December 9th, 2016, 11.30 – 12.15 h

Room A, Kursaal Interlaken

Etiology of cardiovascular complications in CKD

Prof. Patrice Ambühl,
Stadtspital Waid, Zürich

How to prevent electrolyte imbalance in CKD patients?

Dr. Fabien Stucker,
Hôpital de la Providence, Neuchâtel

Friday, December 9

11.30-12.15 Satellite Symposia
Sponsored by VIFOR  **Vifor Pharma Room A**

Cardiovascular complications in CKD patients:
current and emerging new options to reduce risk factors

Etiology of cardiovascular complications in CKD
Patrice Ambühl, Zürich

How to prevent electrolyte imbalance in CKD patients?
Fabien Stucker, Neuchâtel

11.30-12.15 Sponsored by OTSUKA  **Room B**

JINARC® – a novel disease
modifying treatment option for ADPKD

Welcome & Introduction
Olivier Bonny, Lausanne

Identifying patients with rapid progression in ADPKD
Olivier Devuyst, Zurich

Clinical experience, practicalities and patient cases
Roman-Ulrich Müller, Köln (D)

Q&A session moderated by
Olivier Bonny, Lausanne

11.30-12.15 **Pflege in der Nephrologie / Soins en Néphrologie / Cure in Nefrologia**
*Vorsitz: Claudia Studer, Zürich; Ursula Dietrich, Bern;
Irma König, Bellinzona*

Care management auf der Dialyse
Care management in dialisi
Care management sur la Dialyse
Jacqueline Rätz, Baden; Claudia Studer, Zürich

Room Brünig

12.15-13.00 **NEWS FROM IICT (Investigator Initiated Clinical Trials) Room A**

12.15-12.40 **IICT Study – I: NOSTONE Trial**
Daniel Fuster, Bern

12.40-13.00 **IICT Study – II: PRESERVE-TRANSPLANT STUDY**
Nilufar Mohebbi, Zürich

Friday, December 9



JINARC® – a novel disease modifying treatment option for ADPKD

An Otsuka-sponsored symposium

Friday, 9th December 2016

11:30 – 12:15

SGN-SSN 2016,
Congress Centre Kursaal
Interlaken, Room B

PROGRAMME AND SPEAKERS:

Welcome & Introduction
Prof. Olivier Bonny, CHUV Lausanne

Identifying patients with rapid progression in ADPKD
Prof. Olivier Devuyst, University of Zurich

Clinical experience, practicalities and patient cases
PD Roman-Ulrich Müller, University Hospital, Köln

Q&A session moderated by
Prof. Olivier Bonny



LET'S START AT THE BEGINNING



12.15-13.00	<p>Pflege in der Nephrologie / Soins en Néphrologie / Cure in Nefrologia <i>Vorsitz: Claudia Studer, Zürich; Ursula Dietrich, Bern; Irma König, Bellinzona</i></p> <p>Room Brünig</p> <p>L'évaluation clinique de la fistule artério-veineuse native Valutazione clinica della fistola artero-venosa nativa Klinische Evaluation der nativen AV-Fistel <i>André Cunha Moreira Da Silva, Lausanne</i></p> <p>Dialyse aux HUG: peut-on diminuer son impact sur l'environnement et réduire les coûts? Dialisi all'HUG: è possibile diminuire l'impatto ambientale e ridurre i costi? Dialyse im HUG: Können wir Auswirkungen auf die Umwelt minimieren und gleichzeitig die Kosten reduzieren? <i>Eric Guithon, Genève</i></p>	
13.00-14.00	Standing lunch at the exhibition & posters	Exhibition space
14.00-15.00	Oral Parallel Presentations	
14.00-15.00	<p>Clinical Nephrology / Hypertension / Mineral / Electrolytes <i>Chairs: Stefan Farese, Solothurn; Patricia Hirt-Minkowski, Basel</i></p> <p>6 oral presentations</p>	Room A
14.00-15.00	<p>Hemodialysis (HD) / Peritoneal Dialysis (PD) <i>Chairs: Patrick Saudan, Genève; Stephan Segerer, Zürich</i></p> <p>6 oral presentations</p>	Room B
15.00-15.15	Coffee break – Visit of the exhibition & posters	Exhibition space

JINARC® (Tolvaptan) Kurzfachinformation. Indikation: Verlangsamung der Progression von Zystenentwicklung und Niereninsuffizienz bei autosomal-dominanter polyzystischer Nierenerkrankung (ADPKD) bei Erwachsenen mit chronischer Nierenerkrankung (CKD) (Stad. 1 - 3 zu Behandlungsbeginn) mit Anzeichen für rasch fortschreitende Erkrankung. **Dosierung:** 2 x täglich als geteilte Dosis von 45 mg + 15 mg (Anfangsdosis), Dosis titration auf 60 mg + 30 mg oder 90 mg + 30 mg. Die Patienten müssen die höchste verträgliche Dosis Tolvaptan erhalten. Die Tolvaptan-Therapie darf nur von Ärzten eingeleitet und beaufsichtigt werden, die Erfahrung in der Behandlung von ADPKD haben und denen die Risiken einer Tolvaptan-Behandlung einschliesslich der Hepatotoxizität sowie die notwendigen Überwachungsmaßnahmen vollumfänglich bekannt sind. **Kontraindikation:** Überempfindlichkeit gegen den Wirkstoff oder sonstige Bestandteile; erhöhte Leberenzyme u./o. Anzeichen oder Symptome einer Leberschädigung vor der Einleitung der Behandlung, die die Anforderungen für ein dauerhaftes Absetzen von Tolvaptan erfüllen; Volumendepletion; Hyponatriämie; Patienten, die Durst nicht wahrnehmen, oder auf Durst nicht reagieren können; Schwangerschaft; Stillzeit. **Warnhinweise und Vorsichtsmassnahmen:** Tolvaptan wurde mit idiosynkratischen Zunahmen der Alanin- und Aspartat-Aminotransferase (ALT und AST) Spiegel und in seltenen Fällen mit einer gleichzeitigen Erhöhung des Gesamtbilirubins (BT) in Verbindung gebracht. Um das Risiko von erheblichen und/oder irreversiblen Leberschäden zu verringern, sind Bluttests zur Bestimmung der Lebertransaminasen und des Bilirubins vor Beginn der Behandlung mit Jinarc, danach monatlich für 18 Monate und danach regelmässig alle 3 Monate erforderlich. Die gleichzeitige Überwachung auf Symptome, die auf Leberschäden hinweisen können (wie Müdigkeit, Appetitlosigkeit, Übelkeit, Beschwerden im rechten Oberbauch, Erbrechen, Fieber, Hautausschlag, Juckreiz, dunkler Urin oder Gelbsucht), wird empfohlen. Dehydrierung, Harnausschlussobstruktion, Flüssigkeits- und Elektrolythaushalt, abnormale Serumnatriumspiegel, Anaphylaxie, Diabetes mellitus, erhöhte Harnsäurewerte, CYP3A- und P-gp-Induktoren. **Interaktionen:** Mässige oder starke CYP3A-Inhibitoren; starke CYP3A- und P-gp-Induktoren; CYP3A-, CYP2C9-, P-gp- und Transporter-Substrate; Diuretika oder nicht diuretische Antihypertensiva; Vasopressin-Analoga. **Unerwünschte Wirkungen: sehr häufig:** Polydipsie, Kopfschmerzen, Schwindel, Durchfall, Mundtrockenheit, Nykturie, Pollakisurie, Polyurie, Müdigkeit, Durst; **häufig:** Dehydratation, Hyponatriämie, verminderter Appetit, Hyperurikämie, Hyperglykämie, Schlaflosigkeit, Herzklopfen, Dyspnoe, Blähungen, Verstopfung, Dyspepsie, gastroösophageale Refluxkrankheit, gestörte Leberfunktion, Exanthem, Juckreiz, Muskelkrämpfe, Asthenie, erhöhte Alanin-Aminotransferase, erhöhte Aspartat-Aminotransferase, Gewichtsabnahme. **Packungen:** 28 Tabletten: 15, 30 mg Tolvaptan. 56 Tabletten: 28 x 45 mg + 28 x 15 mg Tolvaptan. 56 Tabletten: 28 x 60 mg + 28 x 30 mg Tolvaptan. 56 Tabletten: 28 x 90 mg + 28 x 30 mg Tolvaptan. Konsultieren Sie bitte vor einer Verschreibung die vollständige Fachinformation, die auf der Homepage von Swissmedic unter www.swissmedicinfo.ch publiziert ist. **Abgabekategorie:** A, **Zulassungsinhaber:** Otsuka Pharmaceutical (Switzerland) GmbH, Sägereistrasse 20, 8152 Glattbrugg. **Stand:** Februar 2016 (V001).

Oral communications

Oral Parallel Presentations

14.00-15.00 **Clinical Nephrology / Hypertension / Mineral / Electrolytes** **Room A**
Chairs: Stefan Farese, Solothurn; Patricia Hirt-Minkowski, Basel

OC 13 **Comparison of furosemide/fludrocortisone with ammonium chloride test in the diagnosis of incomplete dRTA in recurrent stone formers: a prospective study (NCCR project)**
Nasser Dhayat¹, Ganesh Pathare¹, Daniel Fuster¹
¹University Hospital of Bern, Division of Nephrology, Hypertension and Clinical Pharmacology and Institute of Biochemistry and Molecular Medicine, Bern

OC 14 **Changes of Urinary Risk Profile after Short Dietary Intervention in Swiss Kidney Stone Formers**
Harald Seeger¹, Andrea Kaelin¹, Pietro Ferraro², Patrice Ambuehl³, Robert Unwin⁴, William Robertson⁵, Carsten Wagner⁶, Nilufar Mohebbi¹
¹Division of Nephrology, University Hospital Zurich, Zurich; ²Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Roma, Italy; ³Renal Division, Stadtspital Waid, Zurich; ⁴Centre for Nephrology, University College London, London, UK; ⁵Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford, UK; ⁶Institute of Physiology, University of Zurich, Zurich

OC 15 **Serum calcification propensity is associated with renal tissue oxygenation and resistive index in patients with CKD or Hypertension**
Menno Pruijm¹, Yimin Lu², Fatma Megdiche¹, Bastien Milani¹, Bruno Vogt³, Matthias Bachtler⁴, Michel Burnier¹, Andreas Pasch⁴
¹University Hospital of Lausanne (CHUV), Lausanne; ²Division of Nephrology, Sion; ³Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, University Hospital, Bern; ⁴Department of Clinical Research, University Hospital of Bern, Bern

OC 16 **Association of kidney stone with chronic cadmium exposure in the general adult population**
Sonia Plaza Wüthrich¹, Menno Pruijm², Daniel Ackermann³, Idris Guessous⁴, Georg Ehret⁵, Sandrine Estoppey Younes¹, Antoinette

Oral communications

Pechère-Bertschi⁶, Judit Jenny-Burri⁷, Max Haldimann⁷, Bruno Vogt⁸, Pierre-Yves Martin⁹, Michel Burnier¹⁰, Murielle Bochud¹, Belen Ponte⁹
¹Institute of Social and Preventive Medicine (IUMSP), University Hospital of Lausanne, Lausanne; ²Service of Nephrology, University Hospital of Lausanne, Lausanne; ³Clinic for Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital and University of Bern, Bern; ⁴Unit of Population Epidemiology, University Hospital of Geneva, Geneva; ⁵Department of Cardiology, University Hospital of Geneva, Geneva; ⁶Department of Community Medicine and Primary Care and Emergency Medicine, University Hospital of Geneva, Geneva; ⁷Swiss Federal Office of Food Security and Veterinary Affairs, Bern; ⁸Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, University Hospital, Bern; ⁹Department of Nephrology, University Hospital of Geneva, Geneva; ¹⁰University Hospital of Lausanne (CHUV), Lausanne

OC 17 **Resistant hypertensive patients display lower exosomal thiazide-sensitive NaCl cotransporter expression after renal denervation. NCCR Kidney.CH project**
Olivier Bonny¹, Fanny Durussel², Candice Stoudmann², Marc Maillard³, Johannes Loffing⁴, Grégoire Wuerzner¹
¹University Hospital Lausanne (CHUV), Lausanne; ²Department of Pharmacology and Toxicology, University of Lausanne, Lausanne; ³Service of Nephrology, University Hospital of Lausanne, Lausanne; ⁴Institute of Anatomy, University of Zurich, Zurich

OC 18 **Kidney stone formers change nutritional habits at three months**
Olivier Bonny¹, Daniel Fuster², Nilufar Mohebbi³, Thomas Hernandez⁴, Min-Jeong Kim⁵, Nasser Dhayat⁶, Catherine Stoermann⁷, Michael Mayr⁸, Grégoire Wuerzner¹, Harald Seeger⁹, Grazia Cereghetti¹⁰, Beat Roth⁶, Carsten Wagner¹¹
¹University Hospital Lausanne (CHUV), Lausanne; ²University Hospital of Bern, Division of Nephrology, Hypertension and Clinical Pharmacology and Institute of Biochemistry and Molecular Medicine, Bern; ³Division of Nephrology, University Hospital, Zurich; ⁴University Hospital Geneva (HUG), Geneva; ⁵University Hospital Basel, Basel; ⁶University Hospital of Bern, Bern; ⁷Division of Nephrology, Geneva University Hospitals, Geneva; ⁸Service of Nephrology, Basel University Hospital, Basel; ⁹University Hospital Zurich, Zurich; ¹⁰NCCR Kidney.CH; ¹¹Institute of Physiology, University of Zurich, Zurich

Oral communications

Oral Parallel Presentations

14.00-15.00 Hemodialysis (HD) / Peritoneal Dialysis (PD) **Room B**

Chairs: Patrick Saudan, Genève; Stephan Seegerer, Zürich

OC 19 Elbasvir/Grazoprevir (EBR/GZR) Treatment of Hepatitis C Virus (HCV) Infection in Patients with Chronic Kidney Disease (CKD) Stage 4/5: Clinical, Virological, and Health-Related Quality of Life Outcomes in the C-SURFER Study

Annette Bruchfeld¹, David Roth², Paul Martin², David Nelson³, Pol Stanislas⁴, Maria Carlota Londoño⁵, Daniele Viviani⁶, Shyan Wan⁷, Jeanmarie Arduino⁷, Michael Robertson⁷, Bachyen Nguyen⁷, Janice Wahl⁷, Eliav Barr⁷, Wayne Greaves⁷

¹Karolinska Institute, Stockholm (SE); ²University of Miami, Miami, FL (US); ³University of Florida, Gainesville, FL (US); ⁴Unité d'Hépatologie, Hôpital Cochin, Université Paris Descartes. UMS20, Institut Pasteur, Paris (FR); ⁵Liver Unit, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, Barcelona (ES); ⁶Merck Sharp and Dohme, Worldwide; ⁷Merck & Co., Inc. Kenilworth, NJ (US)

OC 20 Mortality and other relevant clinical endpoints in the Swiss dialysis population for the 2015 census

Rebecca Winzeler, Patrice Ambuehl
Renal Division, Stadtspital Waid Zurich

OC 21 Marsupialized peritoneal dialysis catheter: technique description and clinical practice advantages

Hilary Riva¹, Olivier Giannini², Stefano Mangano³, Claudio Minoretti³, Daniela Garzoni¹, Giuseppe Bonforte¹

¹Nephrology and Dialysis Department, Beata Vergine Hospital, Mendrisio; ²Internal Medicine Department, Ospedale Beata Vergine, Mendrisio; ³Nephrology and Dialysis department, Sant'Anna Hospital, Como (IT)

Oral communications

OC 22 Real-Time benchmarks and the clinical information catalogue: an innovative user-friendly vascular access register

Hilary Riva¹, Olivier Giannini², Alan Valnegri³, Adriana Degiorgi³, Angela Greco⁴, Luca Gabutti⁵, Lorenzo Berwert⁵, Carlo Schoenholzer⁶, Silvio Pianca⁶, Giorgia Bianchi⁷, Luca Giovannacci⁸, Stephan Engelberger⁸; Giuseppe Bonforte¹

¹Nephrology and Dialysis Department, Beata Vergine Hospital, Mendrisio; ²Internal Medicine Department, Beata Vergine Hospital, Mendrisio; ³Quality and Patient Safety Department, Regional Hospital Lugano, Lugano; ⁴Quality and Risk Manager, La Carità Hospital Locarno, Locarno; ⁵Department of Internal Medicine and Nephrology, San Giovanni Hospital, Bellinzona; ⁶Nephrology and Dialysis Department, Regional Hospital Lugano; ⁷Nephrology Unit, La Carità Hospital, Ente Ospedaliero Cantonale (EOC), Locarno; ⁸Vascular Surgery Department, Regional Hospital Lugano

OC 23 Increasing dialysate magnesium improves serum calcification propensity: The SoloMag study

Stefan Farese¹, Dominik Uehlinger², Marc Huguenot², Nora Bienz¹, Philippe Walter³, Andrea Stampfli³, Matthias Bachteler², Andreas Pasch⁴

¹Department of Nephrology, Bürgerspital, Solothurn; ²Department of Nephrology, University Hospital of Bern, Bern; ³Laborinstitut, Bürgerspital, Solothurn; ⁴Calciscon AG, Bern

OC 24 The serum calcification propensity of hemodialysis patients is strongly modified by serum phosphate, magnesium and bicarbonate

Florian Buchkremer¹, Andreas Pasch², Andreas Bock¹

¹Kantonsspital Aarau, Aarau; ²Department of Clinical Research, University Hospital of Bern, Bern

Jardiance®
(empagliflozin)



JAA



Empagliflozin:
Das **einzigste** orale Anti-
diabetikum nach Metformin
mit einer nachgewiesenen
Reduktion der
Gesamtmortalität:
-30 %^{#§1*}

- Anhaltende Senkung von HbA_{1c}² und Gewicht^{1,2*}
- 1x täglich eine Dosis³
- Bewährtes Sicherheitsprofil^{1,3-6}

1. Zinman B., et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. NEJM. DOI: 10.1056/NEJMoal504720. 2. DeFronzo RA. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015 Mar;38(3):384-93. 3. Jardiance® Fachinformation. Stand Februar 2016. www.swissmedicinfo.ch. 4. Jardiance MetF Fachinformation. Stand September 2015. www.swissmedicinfo.ch. 5. Liakos A., et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism 16: 984-993, 2014. 6. Doley G. Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials. Journal of Diabetes DOI: 10.1111/1753-0407.12278. 7. Massnahmen zur Blutzuckerkontrolle bei Patienten mit Diabetes mellitus Typ 2: Empfehlung der SGED, 24. August 2016. http://sgedssed.ch

Jardiance®: SGLT-2-Inhibitor. Zusammensetzung: Empagliflozin 10 mg, enthält Laktose. **Indikation:** Diabetes mellitus Typ 2 (DMT2). Als Monotherapie bei Patienten, bei denen Metformin aufgrund von Kontraindikationen oder Unverträglichkeiten nicht eingesetzt werden kann. In Kombination mit Metformin und/oder einem Sulfonharnstoff, oder Insulin (mit oder ohne Metformin und/oder einem Sulfonharnstoff). **Dosierung:** 1x 10 mg / Tag. Die Anwendung von Empagliflozin bei Patienten im Alter von ≥ 85 Jahren wird nicht empfohlen. **Kontraindikationen:** Überempfindlichkeit gegenüber dem Wirkstoff oder einem der Hilfsstoffe. **Vorsichtsmassnahmen:** Typ-1-Diabetes oder diabetische Ketoazidose. Jardiance zeigte ähnliche Hypoglykämieraten wie Placebo. Bei der Kombination von Jardiance mit Sulfonharnstoffen oder Insulin ist Vorsicht geboten, ev. Dosisreduktion des Sulfonharnstoffes resp. Insulins wegen möglicher Hypoglykämien. Jardiance wird zur Anwendung bei Patienten mit einer eGFR < 45 ml/min/1,73 m² wegen abnehmender Wirksamkeit nicht empfohlen. Während der Anwendung von Jardiance sollte die Nierenfunktion regelmässig überprüft werden. Die Anwendung von Empagliflozin bei Patienten mit schwerer Leberfunktionsstörung oder mit deutlicher (mehr als dreifacher) Erhöhung der Transaminasen wird wegen begrenzter Erfahrung nicht empfohlen. Empagliflozin kann durch osmotische Diurese potentiell eine orthostatische Hypotonie auslösen; besondere Vorsicht bei Patienten mit bekannter orthostatischer Hypotonie, Patienten unter antihypertensiver Therapie, älteren Patienten sowie Patienten mit bekannter kardiovaskulärer und/oder cerebrovaskulärer Erkrankung. Einnahme während der Schwangerschaft und Stillzeit nicht empfohlen. **Interaktionen:** Empagliflozin führt zu keiner Hemmung, Inaktivierung oder Induktion von CYP450-Isoenzymen. A4. Die gleichzeitige Anwendung von Digoxin, einem P-gp-Substrat, mit Empagliflozin führte zu einer Erhöhung der AUC von Digoxin. Patienten unter Digoxin sollten entsprechend beobachtet werden. Empagliflozin kann die diuretische Wirkung von Thiazid- und Schleifendiuretika verstärken und das Risiko für Dehydratation und Blutdruckabfall erhöhen. **Unerwünschte Wirkungen:** Monotherapie: Vaginaler Soor, Vulvovaginitis, Balanitis und andere Infektionen des Genitaltrakts, Harnwegsinfekte, Volumenmangel, Vermehrtes Wasserlassen, Durst. In Kombination Sulfonharnstoffen/Insulin: Hypoglykämien. Weitere, vollständige Fachinformation. **Packungen:** Filmtabletten zu 10mg: 30 und 90. Liste B. Kassenzulässig ab 1.1.2015. Stand der Information Februar 2016, die vollständige Fachinformation ist auf der Homepage von Swissmedic (www.swissmedic.ch) oder unter www.swissmedicinfo.ch publiziert. Boehringer Ingelheim (Schweiz) GmbH, Hochbergerstrasse 60B, Postfach, 4002 Basel.

* JARDIANCE® ist nicht zugelassen zur Gewichts- und Mortalitätsreduktion.
¹ Als Zusatztherapie zum Standard-of-care bei 120 Patienten mit bestehender CV-Erkrankung (≥ 1 der folgenden Diagnosen: Myokardinfarkt, einfache und multiple disseminierte Arterienkrankheit, instabile Angina Pectoris, Hirnschlag, PAVK)
² EMPA-REG OUTCOME® Primärer Endpunkt (gepoolt Empagliflozin 10 mg & 25 mg [in der Schweiz nicht zugelassen]): kardiovaskulärer Tod, nicht fataler Myokardinfarkt und nicht fataler Hirnschlag (3-Funkt MACE); HR 0,86 (95-02 % CI 0,74, 0,99) p=0,0382. 25 mg: HR 0,86 (95 % CI 0,73, 1,02), 10 mg: HR 0,85 (95 % CI 0,72, 1,01). HRs des primären und der wichtigsten sekundären Endpunkte von 10 mg resp. 25 mg Empagliflozin vs. Placebo waren nahezu identisch mit den gepoolten Analysen.
³ In Bezug auf die aktuell bessere Datenlage bezüglich kardiovaskulärer und mikrovaskulärer Endpunkte.

Friday, December 9

15.15-16.30	Hot Topics <i>Chairs: Isabelle Binet, St. Gallen; Luca Gabutti, Bellinzona</i>	Room A
15.15-15.40	Dialysis withdrawal and palliative care in Nephrology Wim Van Biesen, Ghent (BE)	
15.40-16.05	Herbal remedies: do they harm the kidney? Valerie Luyckx, Zürich	
16.05-16.30	Can we influence medication adherence? Sonja Beckmann, Basel	
16.30	Farewell Pierre-Yves Martin, Genève	Room A

Poster presentations

Basic science / Genetics / Experimental Nephrology

- P 01** **Renal arterial resistive index in patients with lupus nephritis: correlation with disease activity and biopsy parameters**
Mohamed Hasab, Eman Khalil
Department of Internal Medicine, Medical Research Institute, Alexandria University, Alexandria, Egypt (EG)
- P 02** **An in vitro model of idiopathic membranous nephropathy reveals PLA2R- and complement-dependent pathways of podocyte injury**
George Haddad¹, Rudolf Wüthrich², Andreas Kistler³
¹University of Zurich, Zurich; ²Division of Nephrology, University Hospital Zurich, Zurich; ³Cantonal Hospital Frauenfeld, Frauenfeld
- P 03** **Demography of the dialysis population in Switzerland**
Rebecca Winzeler, Patrice Ambuehl
Renal Division, Stadtspital Waid Zurich
- P 04** **Familial Nephrotic Syndrome caused by COQ2 mutations, an inherited mitochondriopathy**
Milena Voskanyan¹, Sofi Sarinyan¹, Ariana Gaspert², Carsten Bergmann³, Stefanie Weber⁴, Ernst Leumann⁵, Ashot Sarkissian¹
¹Nephrology Department, "Arabkir" Medical Centre, Yerevan, Armenia and Yerevan State Medical University, Yerevan, Armenia (AM); ²Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich; ³Bioscientia, Center for Human Genetics, Ingelheim and Department of Nephrology, University of Freiburg, Freiburg, Germany (DE); ⁴University Children's Hospital, Philipps University of Marburg, Marburg, Germany (DE); ⁵University Children's Hospital, Zurich
- P 05** **The Effect of Dietary Amino Acids on Chronic Kidney Disease Progression (NCCR Project)**
Samyuktha Pillai, Simone Camargo, François Verrey
University of Zurich, Zurich

Poster presentations

- P 06** **Fetuin-A Aggravates Lipotoxicity in Podocytes via Interleukin-1 Signaling**
Jana Orellana¹, Kapil Kampe¹, Friederike Schulze², Jonas Sieber³, Andreas W. Jehle¹
¹Department of Biomedicine, Molecular Nephrology, University Hospital, Basel; ²Department of Biomedicine, Diabetes Research, University Hospital, Basel; ³Harvard Medical School and Division of Nephrology, Brigham and Women's Hospital, Boston, MA (US)
- P 07** **Plasma LysoGb3: A Useful Biomarker to Diagnose Fabry Disease Heterozygotes**
Albina Nowak¹, Thomas Mechtler², Robert Desnick³, David Kasper²
¹University Hospital Zurich, Zurich; ²ARCHIMED Life Science, Vienna (AT); ³Icahn School of Medicine at Mount Sinai, New York (US)
- P 08** **Reduced β -catenin levels affect Uromodulin expression in mouse kidneys (NCCR project)**
Stefan Rudloff, Ajay Panakal, Uyen Huynh-Do
Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, University Hospital, Bern
- P 09** **The allele frequency spectrum of PCSK9 mutations in the Swiss general population**
Li Lin¹, Daniela Baptista¹, Belen Ponte², Menno Pruijm³, Daniel Ackermann⁴, Sandrine Estoppey Younes⁵, Idris Guessous⁶, Fred Paccaud⁵, Markus Mohaupt⁷, Olivier Devuyst⁸, Antoinette Pechère-Bertschi⁹, Michel Burnier¹⁰, Pierre-Yves Martin², François Mach¹, Murielle Bochud⁵, Georg Ehret¹
¹Cardiology, Department of Medicine, Geneva University Hospital, Geneva; ²Department of Nephrology, University Hospital of Geneva; ³Service of Nephrology, University Hospital of Lausanne; ⁴Clinic for Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital and University of Bern; ⁵Institute of Social and Preventive Medicine (IUMSP), University Hospital of Lausanne, Lausanne; ⁶Unit of Population Epidemiology, University Hospital of Geneva; ⁷Department of Clinical Research, University of Bern and Internal Medicine, Sonnenhofklinik, Bern; ⁸Institute of Physiology, Zurich Centre for Integrative Human Physiology, University of Zurich,

Poster presentations

Zurich; ⁹Department of Community Medicine and Primary Care and Emergency Medicine, University Hospital of Geneva, Geneva; ¹⁰University Hospital of Lausanne (CHUV), Lausanne

- P 10** **Lack of Fetuin-A exacerbates interstitial kidney fibrosis**
Kevin Dessalle¹, Stefan Rudloff², Uyen Huynh-Do³,
¹Division of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, University of Bern Medical School and Department of Clinical Research, Bern; ²Clinic for Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital and University of Bern, Bern; ³Department of Nephrology, Hypertension and Clinical Pharmacology, University Hospital Bern, Bern

Transplantation

- P 11** **Rejection phenotypes in the current era of immunosuppression: a single-center analysis**
Caroline Wehmeier¹, Patrizia Amico¹, Patricia Hirt-Minkowski¹, Argyrios Georgalis¹, Gideon Hönger¹, Thomas Menter², Michael Mihatsch², Felix Burkhalter¹, Jürg Steiger¹, Michael Dickenmann¹, Helmut Hopfer², Stefan Schaub¹
¹Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel; ²Institute for Pathology, University Hospital Basel, Basel
- P 12** **Severe hyperfiltration injury in a transplant kidney from a pediatric donor: a case report**
Andrea Fisler¹, Theresia Klima¹, Helmut Hopfer², Felix Burkhalter¹, Andrej Isaak³, Min-Jeong Kim⁴
¹Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel; ²Institute for Pathology, University Hospital Basel, Basel; ³Clinic for Vascular Surgery, University Hospital Basel, Basel; ⁴University Hospital Basel, Basel

Poster presentations

- P 13** **Compartmentalization and confounders of the CXCL10 chemokine as a biomarker for subclinical renal allograft inflammation**
Patricia Hirt-Minkowski¹, Julie Ho², Ang Gao³, Michael T. Koller⁴, Hans Hirsch⁵, Helmut Hopfer⁶, Peter Nickerson², Stefan Schaub¹
¹Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel; ²Transplantation and Nephrology, University of Manitoba, Winnipeg, Manitoba (CA); ³Manitoba Centre for Proteomics and Systems Biology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba (CA); ⁴Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel; ⁵Transplantation and Clinical Virology, Department of Biomedicine, University Hospital Basel, Basel; ⁶Institute for Pathology, University Hospital Basel, Basel
- P 14** **Preservation of kidney function in kidney transplant recipients by alkali therapy (Preserve-Transplant Study)**
Anna Wiegand¹, Nicole Graf², Karine Hadaya³, Spyridon Arampatzis⁴, Thomas F. Mueller¹, Carsten A. Wagner⁵, Rudolf P. Wüthrich¹, Nilufar Mohebbi¹
¹Division of Nephrology, University Hospital Zurich, Zurich; ²Graf Biostatistics, Winterthur; ³Divisions of Nephrology and Transplantation, Geneva University Hospital, Geneva; ⁴Department of Nephrology, Hypertension and Clinical Pharmacology, University Hospital Bern, Bern; ⁵Institute of Physiology, University of Zurich, Zurich

Clinical Nephrology / Hypertension / Mineral / Electrolytes

- P15** **Phosphocalcic markers and calcification propensity for assessment of interstitial fibrosis and vascular lesions in kidney allograft recipients**
Lena Berchtold¹, Belen Ponte¹, Solange Moll², Karine Hadaya¹, Olivia Seyde², Matthias Bachtler³, Jean-Paul Vallee⁴, Pierre-Yves Martin¹, Andreas Pasch³, Sophie de Seigneux¹
¹Department of Nephrology, University Hospital of Geneva, Geneva; ²Department of Clinical Pathology, University Hospital of Geneva, Geneva; ³Department of Clinical Research, University Hospital of Bern, Bern; ⁴Department of Radiology and Medical Informatics, University Hospital of Geneva, Geneva

Poster presentations

- P16** **Airborne interstitial nephritis**
Stefan Kalbermatter¹, Anne Tschacher¹, Peter Graber¹, Marc Gutmann², Helmut Hopfer³, Denes Kiss¹
¹Division of Nephrology, Kantonsspital Baselland, Basel; ²Division of Cardiology, Kantonsspital Baselland, Basel; ³Institute for Pathology, University Hospital Basel, Basel
- P17** **Acute kidney injury in a tertiary hospital: can we learn from medical coding?**
Petra Wiedmann¹, Aurelia Schnyder², Christian Bucher², Dimitri Tsinalis², Isabelle Binet²
¹Medical controlling, Kantonsspital St Gallen, St. Gallen; ²Nephrology and Transplantation medicine, Kantonsspital St Gallen, St. Gallen
- P18** **Risk of brain ischemia due to carotid artery stenosis in the very elderly treated with antihypertensives: a hospital survey**
Jürgen Bohlender¹, Jürg Nussberger², Beate Bohlender³
¹Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, University Hospital, Bern; ²Angiology Service, Centre Hospitalier Universitaire Vaudois, Lausanne; ³General practitioner, Germany
- P19** **Assessment of vascular age with a cuff-based oscillometric method in southern switzerland: results from a drugstore survey.**
Rosaria Del Giorno¹, Luca Bianda², Luca Gabutti¹
¹Department of Internal Medicine and Nephrology, San Giovanni Hospital, Bellinzona; ²Farmacie Spaziosalute, Bissone
- P20** **Acute regulated expression of pendrin in human urinary exosomes (UEs)**
Ganesh Pathare¹, Nasser Dhayat², Nilufar Mohebbi³, Carsten Wagner⁴, Daniel Fuster¹
¹University Hospital of Bern, Division of Nephrology, Hypertension and Clinical Pharmacology and Institute of Biochemistry and Molecular Medicine, Bern; ²University Hospital of Bern, Bern; ³Division of Nephrology, University Hospital, Zurich, Zurich; ⁴Institute of Physiology, University of Zurich, Zurich

Poster presentations

- P21** **Assessing the contact-activation of coagulation during hemodialysis with three different polysulfone filters: a prospective randomized cross-over trial.**
Igor Salvadè¹, Rosaria Del Giorno², Gaetano Lucio Donato¹, Luca Gabutti²
¹Division of Nephrology, Ospedale la Carità, Locarno; ²Department of Internal Medicine, Nephrology and Dialysis Unit, Regional Hospital of Bellinzona and Valli, Ente Ospedaliero Cantonale (EOC), Bellinzona
- P22** **Randomized double-blind placebo-controlled trial assessing the efficacy of standard and low dose hydrochlorothiazide treatment in the prevention of recurrent nephrolithiasis – the “NOSTONE trial”**
Nasser Dhayat¹, Olivier Bonny², Florian Buchkremer³, Thomas Ernandez⁴, Min-Jeong Kim⁵, Irene Koneth⁶, Nilufar Mohebbi⁷, Beat Roth¹, Carlo Schoenholzer⁸, Sven Trelle⁹, Daniel Fuster¹
¹University Hospital Bern, Bern; ²University Hospital Lausanne, Lausanne; ³Kantonsspital Aarau, Aarau; ⁴University Hospital Geneva, Geneva; ⁵University Hospital Basel, Basel; ⁶Kantonsspital St Gallen, St. Gallen; ⁷University Hospital Zurich, Zurich; ⁸Regional Hospital Lugano, Lugano; ⁹University of Bern, Bern
- P23** **Failure of rituximab induction therapy in MPO-ANCA vasculitis**
Ineke Grendelmeier¹, Peter Grendelmeier², Denes Kiss¹
¹Division of Nephrology, Kantonsspital Baselland, Basel; ²Division of Pneumology, University Hospital Basel, Basel
- P24** **The crucial role of a Complement deposition endothelial cells Test in the diagnosis of an atypical HUS**
Lorenzo Berwert, Luca Gabutti
Department of Internal Medicine and Nephrology, San Giovanni Hospital, Bellinzona

Poster presentations

- P25** Occurrence of community-acquired acute kidney injury in patients hospitalized for acute heart failure: impact of Renin-Angiotensin-Aldosterone blocking drugs.
Sarah Rosset-Zufferey¹, Gregory Berra¹, Jérôme Stirnemann¹, Pierre-Yves Martin², Sébastien Carballo¹, Patrick Saudan²
¹Department of General Internal Medicine, Geneva University Hospitals, Geneva; ²Division of Nephrology, Geneva University Hospitals, Geneva
- P26** Penile calciphylaxis – a rare presentation of calciphic uraemic arteriopathy
Judith Engeler Dusel¹, Gregor Kadner², Stephan Nobbe³, Cristoforo Medugno⁴, Andreas Kistler¹
¹Departement of Internal Medicine, Nephrology, Cantonal Hospital Frauenfeld, Frauenfeld; ²Departement of Urology, Cantonal Hospital Frauenfeld, Frauenfeld; ³Dermatologic Outpatient Clinic, Department of Internal Medicine, Cantonal Hospital Frauenfeld, Frauenfeld; ⁴Department of Surgery, Cantonal Hospital Frauenfeld, Frauenfeld
- P27** Minimal change disease in SLE
Dirk Bareiss¹, Ineke Grendelmeier², Helmut Hopfer³, Denes Kiss⁴
¹University Hospital of Baselland, Liestal; ²Kantons; ³Institute for Pathology, University Hospital Basel, Basel; ⁴Division of Nephrology, Kantonsspital Baselland, Basel
- P28** Not always what you expect
Michael Girsberger¹, Thomas Menter², Helmut Hopfer², Patricia Hirt¹, Patrizia Amico¹
¹Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel; ²Institute for Pathology, University Hospital Basel, Basel
- P29** Primary Aldosteronism caused by an unusual "Adrenal Adenoma"
Fatma Megdiche¹, Bryan O'Callaghan², Francesco Doenz¹, Marc Maillard¹, Maurice Matter³, Christian Michel⁴, Michel Burnier¹, Grégoire Wuerzner¹, Olivier Phan¹
¹University Hospital of Lausanne (CHUV), Lausanne; ²Hopital Inter-cantonal de la Broye, Payerne; ³Department of Visceral Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne; ⁴Medical Office, Payerne

Poster presentations

- P30** The influence of Dialysate Bicarbonate Concentration on the Risk of Intradialytic Hypotension; a Retrospective Cross-Sectional Study in Southern Switzerland.
Rosaria Del Giorno¹, Lorenzo Berwert¹, Carlo Schoenholzer², Giorgia Bianchi³, Olivier Giannini⁴, Luca Gabutti¹
¹Nephrology Unit, San Giovanni Hospital, Ente Ospedaliero Cantonale (EOC), Bellinzona; ²Nephrology Unit, Civico Hospital, Ente Ospedaliero Cantonale (EOC), Lugano; ³Nephrology Unit, La Carità Hospital, Ente Ospedaliero Cantonale (EOC), Locarno; ⁴Nephrology Unit, Beata Vergine Hospital, Ente Ospedaliero Cantonale (EOC), Mendrisio
- P31** Fibronectin glomerulopathy in a patient with systemic lupus erythematosus: case report and literature review
Sara De Marchi¹, Brenno Balestra¹, Daniela Garzoni², Helmut Hopfer³, Alessandra Ferrarini⁴, Olivier Giannini¹
¹Internal Medicine Department, Ospedale Beata Vergine, Mendrisio; ²Nephrology and Dialysis Department, Ospedale Beata Vergine, Mendrisio; ³Institute for Pathology, University Hospital Basel, Basel; ⁴Medical Genetics Department, Ospedale San Giovanni, Bellinzona
- P32** Dialysate Chloride: an independent player in shaping the intradialytic hemodynamic pattern. Results from a cross-sectional multi-center study.
Rosaria Del Giorno¹, Lorenzo Berwert¹, Carlo Schoenholzer², Giorgia Bianchi³, Olivier Giannini⁴, Luca Gabutti¹
¹Nephrology Unit, San Giovanni Hospital, Ente Ospedaliero Cantonale (EOC), Bellinzona; ²Nephrology Unit, Civico Hospital, Ente Ospedaliero Cantonale (EOC), Lugano; ³Nephrology Unit, La Carità Hospital, Ente Ospedaliero Cantonale (EOC), Locarno; ⁴Nephrology Unit, Beata Vergine Hospital, Ente Ospedaliero Cantonale (EOC), Mendrisio
- P33** Comparative Analysis of the Long-Term Effect of Two Families of High-Flux Polysulfone Dialysers on Platelet Count: a Retrospective Cross-Sectional Study in Southern Switzerland.
Rosaria Del Giorno¹, Lorenzo Berwert¹, Carlo Schoenholzer², Giorgia Bianchi³, Olivier Giannini⁴, Luca Gabutti¹
¹Nephrology Unit, San Giovanni Hospital, Ente Ospedaliero Cantonale (EOC), Bellinzona; ²Nephrology Unit, Civico Hospital, Ente Ospedaliero

Poster presentations

- Cantonale (EOC), Lugano; ³Nephrology Unit, La Carità Hospital, Ente Ospedaliero Cantonale (EOC), Locarno; ⁴Nephrology Unit, Beata Vergine Hospital, Ente Ospedaliero Cantonale (EOC), Mendrisio
- P34** **The yo-yo Hemodynamic effect of Dialysate Potassium. A Retrospective Cross-sectional Study.**
Rosaria Del Giorno¹, Lorenzo Berwert¹, Carlo Schoenholzer², Giorgia Bianchi³, Olivier Giannini⁴, Luca Gabutti¹
¹Nephrology Unit, San Giovanni Hospital, Ente Ospedaliero Cantonale (EOC), Bellinzona; ²Nephrology Unit, Civico Hospital, Ente Ospedaliero Cantonale (EOC), Lugano; ³Nephrology Unit, La Carità Hospital, Ente Ospedaliero Cantonale (EOC), Locarno; ⁴Nephrology Unit, Beata Vergine Hospital, Ente Ospedaliero Cantonale (EOC), Mendrisio
- P35** **Polysulfone hemodialysis membranes and Intra-Dialysis Blood Pressure Variability: a multicenter observational survey**
Rosaria Del Giorno¹, Lorenzo Berwert¹, Carlo Schoenholzer², Giorgia Bianchi³, Olivier Giannini⁴, Luca Gabutti¹
¹Nephrology Unit, San Giovanni Hospital, Ente Ospedaliero Cantonale (EOC), Bellinzona; ²Nephrology Unit, Civico Hospital, Ente Ospedaliero Cantonale (EOC), Lugano; ³Nephrology Unit, La Carità Hospital, Ente Ospedaliero Cantonale (EOC), Locarno; ⁴Nephrology Unit, Beata Vergine Hospital, Ente Ospedaliero Cantonale (EOC), Mendrisio
- P36** **Clinical Management and Inter-Institutional Variability of Renal Anemia Determinants among Dialysis Units in Southern Switzerland**
Anna Zasa¹, Rosaria Del Giorno², Lorenzo Berwert², Carlo Schoenholzer³, Giorgia Bianchi⁴, Olivier Giannini⁵, Luca Gabutti²
¹Ente Ospedaliero Cantonale, La Carità Hospital, Locarno; ²Nephrology Unit, San Giovanni Hospital, Ente Ospedaliero Cantonale (EOC), Bellinzona; ³Nephrology Unit, Civico Hospital, Ente Ospedaliero Cantonale (EOC), Lugano; ⁴Nephrology Unit, La Carità Hospital, Ente Ospedaliero Cantonale (EOC), Locarno; ⁵Nephrology Unit, Beata Vergine Hospital, Ente Ospedaliero Cantonale (EOC), Mendrisio

Poster presentations

- P37** **Bile Cast Nephropathy: The unknown dangers of online shopping**
Andrea Fisler¹, Tobias Breidhardt², Nadine Schmidlin², Helmut Hopfer³, Michael Dickenmann¹, Katrin König¹, Patricia Hirt-Minkowski¹
¹Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel; ²Department of Internal Medicine, University Hospital Basel, Basel; ³Institute for Pathology, University Hospital Basel, Basel
- P38** **Successful pregnancy outcome in a patient with turner syndrome and renal malformation: a case-report**
Claudia Ferrier¹, Curzio Solca¹, Luigi Cornalba¹, Gianni Giudici²
¹Nefrocentro Clinica Luganese, Lugano; ²Studio Dr. Gianni Giudici, Lugano
- P39** **Kidney failure after long-term low-dose methotrexate therapy: a case-report**
Curzio Solca¹, Christian Garzoni², Luigi Cornalba¹, Claudia Ferrier¹
¹Nefrocentro Clinica Luganese, Lugano; ²Department of internal medicine, Clinica Luganese, Lugano
- P40** **Scleroderma renal crisis: a serious complication**
Katrin König¹, Andrea Fisler¹, Cédric Jaeger¹, Helmut Hopfer², Diego Kyburz³, Patricia Hirt¹
¹Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel; ²Institute for Pathology, University Hospital Basel, Basel; ³Department of Rheumatology, University Hospital Basel, Basel
- P41** **Unsuccessful treatment with abatacept of a case of focal segmental glomerulosclerosis (FSGS) recurrence after kidney transplantation**
Leano Violo¹, Marianna De Francesco¹, Giulia Bedino¹, Mauro Imperiali², Thomas Müller³, Carlo Schoenholzer⁴, Silvio Pianca⁵
¹Division of Nephrology, Ospedale Regionale di Lugano, Lugano; ²Department of laboratory medicine (EOLAB), Ospedale regionale di Lugano, Lugano; ³Dpt of Nephrology, University Hospital Zurich, Zurich; ⁴Regional Hospital Lugano, Lugano; ⁵Nephrology and Dialysis Department, Regional Hospital Lugano, Lugano

Poster presentations

- P42** **24h-ambulatory blood pressure monitoring and left ventricular hypertrophy in chronic kidney disease (CKD)**
David Jaques¹, Belen Ponte², Hajo Muller³, Chantal Martinez², Sophie de Seigneux², Pierre-Yves Martin², Patrick Saudan²
¹Department of General Internal Medicine, Geneva University Hospitals, Geneva; ²Department of Nephrology, University Hospital of Geneva, Geneva; ³Department of Cardiology, University Hospital of Geneva, Geneva
- P43** **Baseline fractional excretion of sodium (FE-Na) may serve as an early diagnostic marker for the development of acute kidney injury in myocardial infarction patients**
Spyridon (Spiros) Arampatzis¹, George Chalikias², Stavros Konstantinides², Dimitrios Tziakas², Uyen Huynh-Do³
¹Bern University Hospital, Department of Nephrology, Hypertension and Clinical Pharmacology, Bern; ²Democritus University of Thrace, Medical School, Department of Cardiology, Komotini, Greece; ³Department of Nephrology, Hypertension and Clinical Pharmacology, University Hospital Bern, Bern

Hemodialysis / Peritoneal Dialysis

- P44** **Exploring predispositions to peritoneal fibrosis in two mouse strains**
Anna Avrova, Sara Namvar, Sarah Herrick, Adrian Woolf
University of Manchester (UK)
- P45** **New access, new problems**
Cedric Jaeger, Felix Burkhalter
Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel
- P46** **Impact of reducing salt content of meals consumed during hemodialysis sessions on hemodynamic stability and interdialytic weight gain**
Menno Pruijm, Anita Brinkley, Sofia Guimaraes, Nadia Ammor, Michel Burnier
University Hospital of Lausanne (CHUV), Lausanne

Poster presentations

- P47** **An iPad application to support training by self-instruction for PD**
Andi Schleich¹, Markus Abegg², Anja Soell³, Patrice Ambuehl¹
¹Renal Division, Stadtspital Waid, Zurich; ²Permanence Zurich, Zurich; ³Canoo Switzerland
- P48** **Unconventional hemodialysis schedule: a single center experience**
Nicola Marangon
MVSanté Dialyse, Genève
- P49** **Analysis of the regional multicenter vascular access survey**
Hilary Riva¹, Olivier Giannini², Luca Gabutti³, Lorenzo Berwert³, Carlo Schoenholzer⁴, Silvio Pianca⁴, Giorgia Bianchi⁵, Stephan Engelberger⁶, Luca Giovannacci⁶, Giuseppe Bonforte¹
¹Nephrology and Dialysis Department, Beata Vergine Hospital, Mendrisio; ²Internal Medicine Department, Beata Vergine Hospital, Mendrisio; ³Department of Internal Medicine and Nephrology, San Giovanni Hospital, Bellinzona; ⁴Nephrology and Dialysis Department, Regional Hospital Lugano, Lugano; ⁵Nephrology Unit, La Carità Hospital, Locarno, Ente Ospedaliero Cantonale (EOC), Locarno; ⁶Vascular Surgery Department, Regional Hospital Lugano, Lugano
- P50** **Colonic angiodysplasia and Peritoneal dialysis: two case reports**
Hilary Riva¹, Olivier Giannini², Stefano Mangano³, Giuseppe Bonforte¹
¹Nephrology and Dialysis Department, Beata Vergine Hospital, Mendrisio; ²Internal Medicine Department, Beata Vergine Hospital, Mendrisio; ³Nephrology and Dialysis department, Sant'Anna Hospital, Como (IT)
- P51** **Prospective arteriovenous access management in clinical practice**
Annette Wons, Max Ramsauer, Christian Bucher, Carina Hüsler, Aurelia Schnyder, Alexander Ritter
Nephrology and Transplantation medicine, Kantonsspital St Gallen, St Gallen
- P52** **Complications and hospital stays in our peritoneal dialysis population (incident patients, 01.01.2015-30.06.2016)**
Elena Rho, Davide Giunzioni, Giulia Bedino, Marianna De Francesco, Silvio Pianca, Carlo Schoenholzer
Division of Nephrology, Ospedale Regionale di Lugano, Lugano


Poster presentations

- P53** **Peritoneal dialysis is possible despite start on hemodialysis due to temporary contraindications: a case series**
Elena Rho, Davide Giunzioni, Giulia Bedino, Marianna De Francesco, Silvio Pianca, Carlo Schoenholzer
Division of Nephrology, Ospedale Regionale di Lugano, Lugano
- P54** **Intradialytic hypotension correlates with age, diastolic blood pressure and relative blood volume decrease**
Andreas Bock
Nephrology Division, Kantonsspital Aarau, Aarau
- P55** **Is peritoneal dialysis a feasible option for end-stage renal disease in patients after liver transplantation and repeated abdominal surgery?**
Anne Dschietzig, Vesna Reinmann, Stefan Farese
Nephrology Department, Bürgerspital, Solothurn
- P56** **Serum calcification propensity is improved by increased dialysate bicarbonate and dialysate magnesium: The BicMag pilot study**
Andreas Pasch¹, Matthias Bachtler², Edward Smith³, Katerina Benackova², Dominik Uehlinger²
¹Calciscon AG, Bern; ²Nephrology Department, University Hospital of Bern, Bern; ³Department of Renal Medicine, Eastern Health Clinical School, Monash University, Melbourne (AU)
- P57** **Therapeutic plasma exchange [tpe] with standard renal replacement equipment: a 10 year single-center experience**
Marianna De Francesco, Leano Violo, Giulia Bedino, Davide Giunzioni, Lisa Pellegrini, Giovanni Isella, Silvio Pianca, Carlo Schoenholzer
Division of Nephrology, Ospedale Regionale di Lugano, Lugano
- P58** **Measuring creatinine in peritoneal dialysate: determination of the glucose correction factor**
Florian Buchkremer, Luca Bernasconi, Andreas Bock
Kantonsspital Aarau, Aarau

Speakers / Moderators

- Ambühl Patrice, **Zürich**
- Beckmann Sonja, **Basel**
- Binet Isabelle, **St. Gallen**
- Bonny Olivier, **Lausanne**
- Burnier Michel, **Lausanne**
- Calcaterra Susanna, **Lugano**
- Cunha Moreira Da Silva André, **Lausanne**
- De Seigneux Sophie, **Genève**
- Dietrich Ursula, **Bern**
- Farese Stefan, **Solothurn**
- Fischer Andreas, **Luzern**
- Flammer Andreas, **Zürich**
- Fuster Daniel, **Bern**
- Gabutti Luca, **Locarno**
- Genovesi Simonetta, **Milan**
- Giannini Olivier, **Mendrisio**
- Golshayan Déla, **Lausanne**
- Guithon Eric, **Genève**
- Hall Andrew, **Zürich**
- Hirt-Minkowski Patricia, **Basel**
- Huynh-Do Uyen, **Bern**
- Kistler Andreas, **Frauenfeld**
- König Irma, **Bellinzona**
- Kurtcuoglu Vartan, **Zürich**
- Lhotta Karl, **Feldkirch**
- Luyckx Valérie, **Zürich**
- Martin Pierre-Yves, **Geneva**
- Minniti Marco, **Mendrisio**
- Mohebbi Nilufar, **Zürich**
- Pallet Nicolas, **Paris**
- Räz Jacqueline, **Baden**
- Saudan Patrick, **Geneva**
- Schaub Stefan, **Basel**
- Schönholzer Carlo, **Lugano**
- Schwarzkopf Ann-Kathrin, **Bern**
- Segerer Stephan, **Zürich**
- Studer Claudia, **Zürich**
- Sumitran-Holgersson Suchitra, **Göteborg**
- Teta Daniel, **Sion**
- Tsinalis Dimitrios, **St. Gallen**
- Van Biesen Wim, **Ghent**
- Verrey François, **Zürich**
- Vogt Bruno, **Bern**
- Wilson Patrick, **Delémont**
- Wüthrich Rudolf, **Zürich**

Plan of exhibition



Exhibitors

Firm	Booth
AbbVie AG	3
Association pour l'information et la Recherche sur les maladies rénales Génétiques – AIRG	6
Alexion Pharma GmbH	28
Amgen Switzerland AG	21
Astellas Pharma AG	4
B. Braun Medical AG	25
Baxter AG	10
Boehringer-Ingelheim (Schweiz) GmbH	5
Bracco Suisse SA	20
CytoSorbents Switzerland GmbH	12
Euromed Swiss AG	8
Forni medical gmbh	19
Fresenius Medical Care (Schweiz) AG	22
Laboratorium Dr. G. Bichsel AG	24
MCM MEDSYS AG	18
Mitsubishi Tanabe Pharma GmbH	9
MSD	29
Neovii Pharmaceuticals AG	16
Novartis Pharma Schweiz AG & Sandoz Pharmaceuticals AG	11
Otsuka Pharmaceutical (Switzerland) GmbH	2
Pro Farma AG	1
Roche Pharma (Schweiz) AG	26
Salmon Pharma GmbH	15
sanofi-aventis (schweiz) ag	27
Shire Switzerland GmbH	13
Swiss Dialysis Registry	33
Terumo BCT Europe N.V.	14
Theramed AG	17
Vifor Pharma	23 / 32
VNPS Verein Nierenpatienten Schweiz	7

Sponsored symposia in alphabetical order



Amgen Switzerland AG, Zug
Parallel Satellite Symposium
Thursday, December 8, 2016
15.30-16.15 / Room A



Boehringer-Ingelheim (Schweiz) GmbH
Parallel Satellite Lunch Symposium
Thursday, December 8, 2016
12.30-13.15 / Room A



Otsuka Pharmaceutical (Switzerland) GmbH, Glattbrugg
Parallel Satellite Symposium
Friday, December 9, 2016
11.30-12.15 / Room B



Vifor SA, Villars-sur-Glâne
Parallel Satellite Symposium
Friday, December 9, 2016
11.30-12.15 / Room A

Advertisement

Fresenius AG

Pro Farma AG

Shire Switzerland GmbH

Boehringer-Ingelheim (Schweiz) GmbH

Association

Association pour l'Information et la Recherche sur les maladies rénales Génétiques (AIRG)



Kind thanks to the municipality of Interlaken for its financial support and welcome



MUNICIPALITY
INTERLAKEN

Kind thanks to all our sponsors

abbvie

AMGEN®

B | BRAUN
SHARING EXPERTISE

 **Boehringer
Ingelheim**

CytoSorbents™

fm forni medical gmbh

bichsel

ALEXION®

 **astellas**
Leading Light for Life

Baxter


BRACCO
LIFE FROM INSIDE

 **EUROMED Swiss**
Medical Distribution Services

 **FRESENIUS
MEDICAL CARE**

MCM MEDSYS
Together to excellence

Kind thanks to all our sponsors

 Mitsubishi Tanabe Pharma GmbH

neovii

 **NOVARTIS**


PRO FARMA

Salmon Pharma
Ein Unternehmen der


MEDICE

SANOFI 


swiss renal registry and quality assessment program


theramed ag
medizinprodukte

 **MSD**


Otsuka


Roche

SANDOZ A Novartis
Division


Shire

TERUMOBCT
Unlocking the Potential of Blood

 **Vifor Pharma**

Save the date: SGN-SSN congress 2017

We would like to invite you to the

49th Annual Meeting of the Swiss Society of Nephrology SGN-SSN
on **December 7-8, 2017** – Forum Fribourg, Granges-Paccots



Please save the dates of December 7-8, 2017 !

We look forward to welcoming you in Forum Fribourg next year !



www.swissnephrology.ch

Schweizerische Gesellschaft für Nephrologie
Soci t  Suisse de N phrologie
Societ  Svizzera di Nefrologia

Kassenzul ssig
(zur Rezidivprophylaxe des
Nierensteins^{1,4})



Urocit[®]

Rezidivprophylaxe des Nierensteins.¹



- **Wirksam u.a. bei Kalziumoxalat-, Kalziumphosphat- und Harns uresteinen²**
- **Abnahme der Steinbildungsrate bei 94% und komplette Remission bei 72% der Patienten³**
- **Kontinuierliche und verz gerte Freisetzung der Wirksubstanz dank WAX-MATRIX-System¹**

Urocit[®] Tabletten **Z:** Kalii citras 1080 mg (10 mEq), Tabletten. **I:** Zur Alkalisierung des Harnes bei Patienten mit Nierensteinen in der Anamnese, zur Rezidivprophylaxe. **D:** Im Allgemeinen ist f r die Anhebung des Urin-pHs auf einen Wert von 6–7 eine Dosis von 30–60 mEq/Tag erforderlich. **KI:** Hyperkal mie, Patienten mit erh htem Risiko f r eine Hyperkal mie, beeintr chtigter Magendarmtransit,  sophagus- bzw. Darmobstruktion oder -strukturen, Magen-Darm-Ulzera, aktive Harnwegsinfektion, eingeschr nkte Nierenfunktion (GFR < 0.7 ml/kg/min), Komedikation mit kaliumsparenden Diuretika oder ACE-Hemmern. **VN:** Ausreichende Fl ssigkeitszufuhr. Vor Therapiebeginn Elektrolyte im Serum bestimmen und Nierenfunktion kontrollieren. Bei Herzinsuffizienz oder anderen schweren Myokardsch digungen m glichst nicht anwenden. Vorsicht bei Myotonia congenita. **UN:** H ufig gastrointestinale St rungen, die weitgehend vermieden werden k nnen, wenn das Pr parat mit gen gend Fl ssigkeit eingenommen wird. **A:** Kaliumsparende Diuretika, ACE-Hemmer, nicht-steroidale Antiphlogistika, periphere Analgetika, Digitalisglykoside, aluminiumhaltige Pr parate, Pr parate, die eine Verlangsamung der gastrointestinalen Transitzeit bewirken (wie z. B. Anticholinergika). **P:** Urocit[®] 100 Tabletten, Abgabekategorie B. Kassenzul ssig (BAG LIM). Ausf hrliche Informationen siehe www.swissmedinfo.ch **Referenzen:** 1. Urocit[®] (Kaliumcitrat); aktuelle Fachinformation auf www.swissmedinfo.ch 2. Tiselius HG et al. Guidelines on Urolithiasis. European Association of Urology. Update March 2008. 3. Robinson MR et al. Impact of long-term potassium citrate therapy on urinary profiles and recurrent stone formation. J Urol. 2009;181(3):1145–50. 4. www.spezialtaetenliste.ch

Zulassungsinhaber: Pro Farma AG, Lindenstrasse 8, CH-6340 Baar, www.profarma.ch

Unklare Nephropatie? Denken Sie an Morbus Fabry



ZNS: Gehirn

TIA, Schlaganfälle, Depression

Augen

Cornea verticillata, Tortuositas vasorum

Ohren

Tinnitus, Vertigo, Hörstörungen

Herz

Linksventrikuläre Hypertrophie (LVH),
prominenter Papillarmuskel, Arrhythmien

Niere

Mikroalbuminurie, Proteinurie,
Niereninsuffizienz

Verdauungstrakt

Diarrhoe, Völlegefühl, Übelkeit, DD zu Diarrhoe-
prädominanter Form des Reizdarmsyndroms

Haut

Angiokeratome, Hypo- und Anhidrose,
Lymphödeme

Peripheres Nervensystem

Small fiber Neuropathie mit neuropathischen
Schmerzen

Nutzen Sie den kostenlosen Diagnoseservice unter:
info@shirepharma.ch

Shire Switzerland GmbH
6301 Zug